RxDoctor Payments Data

Michael Lee, MD

Internal Medicine · Frisco, TXNPI 1447351622

Payments from drug & device makers

$1,509in general payments, 2019–2025

Across 78 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$259
  • Lilly USA, LLC$231
  • Johnson & Johnson$126
  • Exact Sciences$116
  • AstraZeneca$114
  • Pfizer$99
  • plus $564 from 13 others

What the payments were for

  • Food & beverage$1,509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,509 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$91,375
Medicare patients
251
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$64,626
JardianceEmpagliflozin33$55,507
EliquisApixaban34$47,044
JanuviaSitagliptin Phosphate29$41,803
RybelsusSemaglutide21$36,500
XareltoRivaroxaban25$35,611
TrulicityDulaglutide25$34,339
MounjaroTirzepatide26$28,508
FarxigaDapagliflozin Propanediol21$28,482
Repatha SureclickEvolocumab14$16,281
Breo ElliptaFluticasone/Vilanterol25$12,863
Rosuvastatin Calcium476$5,787
Atorvastatin Calcium533$5,133
SynthroidLevothyroxine Sodium54$3,942
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$259$101,12760 claims
Lilly USA, LLCTrulicity, Mounjaro$231$62,84751 claims
Boehringer IngelheimJardiance$73$55,50733 claims
PfizerEliquis$99$47,04434 claims
MerckJanuvia$15$41,80329 claims
Johnson & JohnsonXarelto$126$35,61125 claims
AstraZenecaFarxiga$114$28,48221 claims
GSKBreo Ellipta$33$12,86325 claims
AbbVieSynthroid$71$3,94254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →